X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
obinutuzumab (194) 194
rituximab (124) 124
index medicus (113) 113
humans (91) 91
oncology (82) 82
chronic lymphocytic leukemia (67) 67
hematology (66) 66
open-label (53) 53
chronic lymphocytic-leukemia (51) 51
follicular lymphoma (48) 48
hemic and lymphatic diseases (46) 46
ibrutinib (46) 46
leukemia, lymphocytic, chronic, b-cell - drug therapy (45) 45
cancer (38) 38
lymphomas (37) 37
monoclonal antibodies (37) 37
immune system diseases (36) 36
non-hodgkin-lymphoma (36) 36
cd20 (35) 35
leukemia (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
cll (33) 33
ofatumumab (32) 32
b-cell lymphoma (31) 31
chemotherapy (31) 31
lymphoma (31) 31
anti-cd20 monoclonal-antibody (30) 30
antibodies, monoclonal, humanized - therapeutic use (30) 30
idelalisib (30) 30
obinutuzumab ga101 (30) 30
antineoplastic agents - therapeutic use (29) 29
chlorambucil (29) 29
care and treatment (27) 27
pharmacology & pharmacy (26) 26
previously untreated patients (26) 26
therapy (26) 26
cytotoxicity (25) 25
female (25) 25
ga101 (25) 25
cyclophosphamide (24) 24
immunology (24) 24
aged (23) 23
antibodies, monoclonal, humanized - administration & dosage (23) 23
immunotherapy (23) 23
treatment outcome (23) 23
male (22) 22
monoclonal antibody (20) 20
1st-line treatment (19) 19
anti-cd20 antibody (19) 19
clinical trials (19) 19
fludarabine (19) 19
initial therapy (19) 19
lenalidomide (19) 19
venetoclax (19) 19
multicenter (18) 18
animals (17) 17
bendamustine (17) 17
in-vitro (17) 17
medicine & public health (17) 17
review (17) 17
survival (17) 17
analysis (16) 16
antineoplastic agents - adverse effects (16) 16
middle aged (16) 16
phase-ii trial (16) 16
antigens, cd20 - immunology (15) 15
efficacy (15) 15
non-hodgkins-lymphoma (15) 15
research (15) 15
antibodies, monoclonal - therapeutic use (14) 14
antibodies, monoclonal, humanized - adverse effects (14) 14
antibody (14) 14
antineoplastic agents - administration & dosage (14) 14
apoptosis (14) 14
clinical trials as topic (14) 14
drug therapy (14) 14
hematology, oncology and palliative medicine (14) 14
medicine (14) 14
trial (14) 14
antimitotic agents (13) 13
antineoplastic agents (13) 13
article (13) 13
chemoimmunotherapy (13) 13
disease-free survival (13) 13
phase-ii gauguin (13) 13
antibodies, monoclonal, humanized - pharmacology (12) 12
cd20 antigen (12) 12
medicine, general & internal (12) 12
minimal residual disease (12) 12
adult (11) 11
alemtuzumab (11) 11
chronic lymphatic leukemia (11) 11
comorbidity (11) 11
immunoglobulins (11) 11
internal medicine (11) 11
life sciences (11) 11
medicine, research & experimental (11) 11
monoclonal-antibodies (11) 11
patients (11) 11
safety (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (213) 213
German (5) 5
Polish (3) 3
Czech (2) 2
Spanish (2) 2
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2019, Volume 42, Issue 9, pp. 486 - 486
Journal Article
The Lancet Haematology, ISSN 2352-3026, 08/2019, Volume 6, Issue 8, pp. e391 - e392
Journal Article
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 03/2018, Volume 31, Issue 1, pp. 41 - 48
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 15, pp. 4634 - 4643
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether... 
CD20 | ARISE | MECHANISM | ONCOLOGY | RITUXIMAB | ANTIBODY | PERIPHERAL-BLOOD | DIFFERENTIATION | CYTOTOXICITY | OBINUTUZUMAB
Journal Article
Journal of pharmaceutical sciences, ISSN 0022-3549, 07/2019, Volume 108, Issue 11, pp. 3729 - 3736
The pharmacokinetics (PK) of the anti-CD20 monoclonal antibody obinutuzumab was assessed following single intravenous dosing to cynomolgus monkeys. In... 
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S112 - S113
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2323 - 2325
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2425 - 2437
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 03/2018, Volume 103, Issue 4, pp. 563 - 564
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 02/2019, Volume 60, Issue 3, pp. 833 - 835
Journal Article
TURKISH JOURNAL OF HEMATOLOGY, ISSN 1300-7777, 03/2019, Volume 36, pp. 14 - 14
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 18, pp. 1711 - 1721
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2019, Volume 105, Issue 2, pp. 363 - 375
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have... 
CELL LUNG-CANCER | INTRINSIC RESISTANCE | IMATINIB-RESISTANT | BIM DELETION POLYMORPHISM | OBINUTUZUMAB GA101 | PHARMACOLOGY & PHARMACY | PHASE-I SAFETY | OPEN-LABEL | MONOCLONAL-ANTIBODIES | METABOLIZING-ENZYMES | CHRONIC MYELOID-LEUKEMIA
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.